The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Treatment options for transplant-ineligble myeloma patients: the promise of combination therapies
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, shares some insights into treatment options available for transplant-ineligible multiple myeloma patients. Prof. Jackson first highlights the importance of clearly defining transplant-eligible versus ineligible, and then discusses treatment options available for transplant-ineligible patients, including lenalidomide plus dexamethasone and ixazomib. Prof. Jackson then discusses some clinical trials which have shown that combination therapies are very promising for transplant-ineligible patients, including the MAIA trial (NCT02252172) and the ALCYONE trial (NCT02195479). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Speaker honoraria engagements: Amgen, Takeda, Johnson & Johnson, Sanofi, Celgene and Roche; Research funding: Takeda, Onyx and Celgene; Advisory Boards: Amgen, Takeda, Johnson & Johnson, Oncopeptides, Pfizer, Sanofi, Celgene, GSK and Roche; Board of directors Myeloma UK.
